Corona Remedies Ltd
Corona Remedies Ltd (CORONA) last reported results for the quarter ended Jun 2026, with sales of ₹422 crore and net profit of ₹60 crore. The stock last traded at ₹2,033, a market capitalisation of ₹12,432 crore, on a P/E of 58.6. Over the past 52 weeks the stock has ranged between ₹1,337 and ₹2,292. Figures are as of 6 Oct 2026 and are not real time.
Corona Remedies Ltd share price and key metrics
- Current price
- ₹2,033
- Market cap
- ₹12,432 cr
- Stock P/E
- 58.6
- Book value
- ₹122
- ROE
- 29.5%
- ROCE
- 33.3%
- Dividend yield
- 0.49%
- 52w high / low
- 2292/1337
Metrics as of 6 Oct 2026. Not real time.
Track Corona Remedies Ltd
Cruxal reads every Corona Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Corona Remedies Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 17%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 33%
- TTM
- 28%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 27%
- Last Year
- 30%
Corona Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹422 cr, up 21.6% from ₹347 cr a year earlier. Net profit was ₹60 cr, up 30.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other income | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net profit | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 |
| EPS (₹) | 7.03 | 7.35 | 5.16 | 7.55 | 8.55 | 6.75 | 7.41 | 9.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Corona Remedies Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Operating profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14% | 15% | 20% | 21% | 21% |
| Net profit | 85 | 90 | 149 | 185 | 199 |
| EPS (₹) | 13.89 | 14.80 | 24.43 | 30.27 | 32.54 |
TTM is the trailing twelve months to the most recent quarter.
Corona Remedies Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 686 |
| Borrowings | 28 | 159 | 86 | 165 |
| Other liabilities | 159 | 191 | 237 | 293 |
| Total liabilities | 595 | 831 | 930 | 1,205 |
| Fixed assets | 185 | 384 | 370 | 554 |
| CWIP | 65 | 121 | 186 | 143 |
| Investments | 32 | 26 | 26 | 26 |
| Other assets | 314 | 301 | 348 | 482 |
| Total assets | 595 | 831 | 930 | 1,205 |
As reported by the company. Total assets equal total liabilities by construction.
Corona Remedies Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 103 | 157 | 190 | 229 |
| Cash from investing | -50 | -267 | -84 | -256 |
| Cash from financing | -45 | 99 | -107 | 25 |
| Net cash flow | 8 | -11 | 0 | -1 |
| Free cash flow | 9 | -129 | 99 | 56 |
| CFO / operating profit | 100% | 112% | 97% | 95% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Corona Remedies Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 25% | 32% | 33% |
| Debtor days | 36 | 36 | 36 | 38 |
| Inventory days | 182 | 158 | 200 | 175 |
| Days payable | 163 | 184 | 221 | 206 |
| Cash conversion cycle | 55 | 10 | 14 | 7 |
| Working capital days | 30 | -2 | 9 | -15 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Corona Remedies Ltd shareholding pattern
Promoters held 69.00% at Jun 2026, broadly unchanged since Dec 2025. FIIs 3.63% and DIIs 12.90%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% |
| FIIs | 1.84% | 2.25% | 3.63% |
| DIIs | 6.77% | 7.02% | 12.90% |
| Public | 22.41% | 21.75% | 14.47% |
| No. of shareholders | 31,035 | 19,609 | 20,185 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Corona Remedies Ltd corporate filings
- Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Care Ratings reaffirmed and upgraded ratings for Corona Remedies Limited's bank facilities, indicating improved creditworthiness and financial stabilityCompany Updatehigh impact
Cruxal's analysis: Corona Remedies Limited received a reaffirmation of its long-term bank facility rating at…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Corona Remedies Limited: Significant Stake Divestment by Institutional Investors via Open Market SaleInsider Trading / SASTmedium impact
Cruxal's analysis: Corona Remedies Limited has reported a substantial reduction in shareholding by three…
Read the full analysis - Corona Remedies Limited: Significant Stake Sale by Institutional Investors via Open MarketInsider Trading / SASTmedium impact
Cruxal's analysis: Corona Remedies Limited has witnessed a substantial divestment of equity shares by three…
Read the full analysis - Corona Remedies Ltd announces participation in upcoming analyst/investor meetCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has issued an intimation regarding its participation in an…
Read the full analysis - Corona Remedies Ltd clarifies on recent stock volume movementCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has responded to a clarification request from the exchange regarding…
Read the full analysis - Corona Remedies Ltd announces participation in upcoming analyst and investor conferenceCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has filed an intimation regarding its participation in an…
Read the full analysis - CORONA Remedies Reports Strong Q1 FY27 Performance with 21.9% Revenue Growth and Margin ExpansionCompany Updatehigh impact
Cruxal's analysis: CORONA Remedies Limited delivered a robust Q1 FY27 performance, with revenue growing…
Read the full analysis - Corona Remedies Ltd schedules analyst and investor conferenceCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has issued an intimation regarding a scheduled analyst and investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.